anti-CD19/BCMA CAR NK cells

Phase 1Cell therapy

TThe Children's Hospital of Zhejiang University School of Medicine

anti-CD19/BCMA CAR NK cells is one of 72 biologic programs targeting Autoimmune Disease. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Autoimmune DiseaseActive, not recruiting

Iga NephropathyActive, not recruiting

Autoimmune DiseasePhase 1

Active, not recruiting

Iga NephropathyPhase 1

Active, not recruiting

Competition

Competitive Landscape

150 competitors in Autoimmune Disease

#DrugCompanyPhaseTrials

Myfortic

Novartis

Phase 3

1 2

Remicade

OOrganon and Co

Phase 3

2 3

Atgam

Novartis

Phase 2

2 4

Cytosar

Teva

Phase 2

1 5

Blincyto

Amgen

Phase 2

1 6

Soliris

Rayos

2 8

UPLIZNA

HHorizon Therapeutics Ireland DAC

Phase 2

1 9

Alkeran

AApotex Inc.

Phase 2

1 10

Bicnu

MMelissa K Accordino

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2029

Phase 1Recruiting

Autoimmune Disease

NCT06792799

Q4 2029

Phase 1Recruiting

Autoimmune Disease

NCT07283315

Clinical

Trials by Indication[1]

Autoimmune Disease2 trials

Exploratory Clinical Study of Second-generation CD19/BCMA Chimeric Antigen Receptor NK Cell Injection in Treating Paediatric B Cell-related Autoimmune Diseases

Recruiting·TThe Children's Hospital of Zhejiang University School of Medicine·Phase 1·NCT07283315·12 enrolled

Anti-CD19/BCMA CAR-NK Cells in Patients With B Cell Mediated Autoimmune Disease

Recruiting·TThe Children's Hospital of Zhejiang University School of Medicine·Phase 1·NCT06792799·36 enrolled

IgA Nephropathy1 trial

An Exploratory Clinical Study of Anti-CD19/BCMA Chimeric Antigen Receptor NK Cell Injection in the Treatment of IgA Nephropathy

Withdrawn·JJieyang People's Hospital·Phase 1·NCT06926985

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for anti-CD19/BCMA CAR NK cells. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — anti-CD19/BCMA CAR NK cells compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for anti-CD19/BCMA CAR NK cells. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — The Children's Hospital of Zhejiang University School of Medicine company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Cell therapy[2]
Highest Phase: Phase 1[1]
Company: TThe Children's Hospital of Zhejiang University School of Medicine

anti-CD19/BCMA CAR NK cells

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2029

Q4 2029

Trials by Indication[1]

Autoimmune Disease2 trials

IgA Nephropathy1 trial

References

Drug Info

Quick Facts

Related News